$11.95
−10.02%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$12.48
From 52W high−42.99%
Volume608755.00
Market cap$1.55B
P/E (TTM)—
P/S (TTM)12.9x
Div yield—
Key dataOct 19, 2026
Open
$12.48
From 52W high
−42.99%
Volume
608755.00
Market cap
$1.55B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−36.1x
P/E (TTM)
—
RSI (14)
28.4
MomentumView details →
1D Return
−10.02%
YTD Return
−33.18%
SummaryUpdated Jun 1, 2026
Mesoblast Limited (NASDAQ:MESO) is an Australian biopharmaceutical company founded in 2004 and headquartered in Melbourne. The company specializes in developing and commercializing allogeneic cellular medicines based on mesenchymal stromal cells (MSCs), a type of adult stem cell. Mesoblast went public in 2010 and has since established itself as a pioneer in the regenerative medicine field. The company achieved a significant milestone in 2024 with the FDA approval of <b>RYONCIL</b>, the first mesenchymal stromal cell therapy approved in the United States, marking its transition from a pure development-stage company to one with commercial operations.
Similar companies
Latest newsMore news →
Mesoblast received FDA approval to implement a new potency assay, the T-cell Proliferation Inhibition BioAssay (TIBA), for release and stability monitoring of new commercial lots of its MSC product Ryoncil.26d agoMesoblast Limited reported financial results for the fiscal year ended June 30, 2026, with substantial revenue growth to US$120 million and gross profit of US$104 million.54d ago